---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-24-000116"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:06:31.301335+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q3 revenue $301M (+11.1% YoY); U.S. thrombectomy up 21.2%; raises segment guidance

## Summary
- Revenue $301.0M, +11.1% YoY; net income $29.5M; adjusted EBITDA $56.7M (18.8% margin).
- U.S. thrombectomy revenue $162.1M, +21.2% YoY; VTE franchise grew 32% vs Q3 2023.
- GAAP operating income $35.4M vs $12.6M in Q3 2023; non-GAAP operating income $40.3M.
- Full-year 2024 revenue reaffirmed $1.18-1.20B; U.S. thrombectomy growth expectation raised to 24-25% from 23-25%.
- Wind down of Immersive Healthcare incurred $5M in one-time expenses during Q3 2024.

## SEC filing metadata
- accession: 0001321732-24-000116
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000116/0001321732-24-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173224000116/pen-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-24-000116
- JSON: https://secwatch.observer/filing/0001321732-24-000116.json
- Plain text: https://secwatch.observer/filing/0001321732-24-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.